Clinical TrialJun 12, 2026, 06:16 AM
HUTCHMED Sovleplenib Phase 3 Meets Primary Endpoint; NMPA Priority Review
AI Summary
HUTCHMED announced positive Phase III results for sovleplenib in warm antibody autoimmune hemolytic anemia (wAIHA) from its ESLIM-02 study, presented at the European Hematology Association Congress. The study met its primary endpoint, demonstrating significantly superior efficacy and a favorable safety profile compared to placebo. China's National Medical Products Administration has accepted the New Drug Application for sovleplenib for priority review and granted it Breakthrough Therapy Designation.
Key Highlights
- Sovleplenib Phase III ESLIM-02 study met primary endpoint in wAIHA patients.
- China NMPA accepted NDA for sovleplenib and granted priority review in April 2026.
- NMPA granted Breakthrough Therapy Designation to sovleplenib in March 2026.
- Durable response rate was 66% for sovleplenib vs 15% for placebo (p<0.0001).
- Overall response rate was 70% for sovleplenib vs 22% for placebo (p<0.0001).
- Rescue therapy use was significantly reduced to 16% for sovleplenib vs 54% for placebo.
- Grade ">="3 treatment-emergent adverse events were 43% for sovleplenib vs 59% for placebo.
Price Impact
More from HCM